US FDA's Marks: Gene Therapy Success Could Hinge On Regulatory Convergence
Biologics center's director encourages sponsors to invite other regulators to early FDA meetings in effort to scale up markets.
You may also be interested in...
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.